Perspective Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 19, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $81.00K | $-0.22 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 9, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 20, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | $300.00K | $-0.29 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $400.00K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | $300.00K | $-0.02 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | $300.00K | $-0.02 | – |
| Q4 FY2022 Ended Jun 30, 2022 | Sep 28, 2022 | After market close | $2.50M | $-0.01 | – |
Press releases
Announcements Perspective Therapeutics filed with the SEC
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology
Other events · EX-99.1 to Form 8-K
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Provides Recent Business Highlights and
Results of operations · Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Results of operations · Other events · EX-99.2 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Provides Recent Business Highlights and
Results of operations · Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Results of operations · Other events · EX-99.2 to Form 8-K
Engineering the Alpha Advantage in Targeted Oncology
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Other events · EX-99.3 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Provides Recent Business Highlights and
Results of operations · Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Results of operations · Other events · EX-99.2 to Form 8-K
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Material agreement · Other events · EX-99.2 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Results of operations · Other events · EX-99.1 to Form 8-K
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Results of operations · Other events · EX-99.1 to Form 8-K
Developing the next generation of targeted therapies
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Provides Recent Business Highlights and
Results of operations · Other events · EX-99.1 to Form 8-K
Developing the next generation of targeted therapies
Results of operations · Other events · EX-99.2 to Form 8-K
Corporate Presentation November 2025 NYSE AMERICAN: CATX
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
Results of operations · Other events · EX-99.1 to Form 8-K
Investor Call ESMO 2025 Presentation
Results of operations · Other events · EX-99.2 to Form 8-K
Developing the Next Generation of Targeted Therapies
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Developing the Next Generation of Targeted Therapies
Other events · EX-99.1 to Form 8-K
Perspective Therapeutics Provides Recent Business Highlights and
Results of operations · Other events · EX-99.1 to Form 8-K
Developing the Next Generation of Targeted Therapies
Results of operations · Other events · EX-99.2 to Form 8-K
Developing the Next Generation of Targeted Therapies
Other events · EX-99.1 to Form 8-K
Corporate Presentation July 2025 NYSE AMERICAN: CATX
Other events · EX-99.1 to Form 8-K